Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential

• Published in: British journal of radiology 2010-07, Vol.83 (991), p.596-603
• Main Authors: SKÖLD, K, GORLIA, T, PELLETTIERI, L, GIUSTI, V, H-STENSTAM, B, HOPEWELL, J. W
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents, Alkylating - therapeutic use; Biological and medical sciences; Boron Compounds - therapeutic use; Boron Neutron Capture Therapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine - analogs & derivatives; Dacarbazine - therapeutic use; Disease-Free Survival; Fructose - analogs & derivatives; Fructose - therapeutic use; Glioblastoma - drug therapy; Glioblastoma - radiotherapy; Humans; Investigative techniques, diagnostic techniques (general aspects); Medical sciences; Middle Aged; Neurology; O-Methylguanine-DNA Methyltransferase - genetics; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Tumors of the nervous system. Phacomatoses; Young Adult
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr/56953620

The purpose of this study was to assess the potential of boron neutron capture therapy (BNCT), with a 6-h infusion of the boron carrier l-boronophenylalanine as a fructose preparation (BPA-f), as first-line radiotherapy for newly diagnosed glioblastoma multiforme (GBM). Patient survival data from a Phase II study using BNCT were compared with retrospective data from the two arms of a Phase III study using conventional radiotherapy (RT) in the reference arm and using RT plus concomitant and adjuvant medication with temozolomide (TMZ) in the experimental arm, and were also compared with small subgroups of these patients for whom the methylation status of the MGMT (O(6)-methylguanine-DNA methyltransferase) DNA repair gene was known. Differences in the baseline characteristics, salvage therapy after recurrence and levels of severe adverse events were also considered. The results indicate that BNCT offers a treatment that is at least as effective as conventional RT alone. For patients with an unmethylated MGMT DNA repair gene, a possible clinical advantage of BNCT over RT/TMZ was suggested. BNCT is a single-day treatment, which is of convenience to patients, with mild side effects, which would offer an initial 6 weeks of good-quality life during the time when patients would otherwise be undergoing daily treatments with RT and TMZ. It is suggested that the use of BNCT with a 6-h infusion of BPA-f should be explored in a stratified randomised Phase II trial in which patients with the unmethylated MGMT DNA repair gene are offered BNCT in the experimental arm and RT plus TMZ in the reference arm.